Liso-cel,(Breyanzi, Bristol Myers Squibb, Princeton, NJ, USA) an autologous CD19-directed CAR T-cell therapy, was studied in patients with RR CLL/SLL in the TRANSCEND CLL 004 study [171,172]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.